Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other financing activities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Other financing activities for 3 consecutive years, with $1.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other financing activities fell 10.13% year-over-year to $1.2 million, compared with a TTM value of $1.6 million through Dec 2024, up 217.08%, and an annual FY2024 reading of $4.0 million, down 1.21% over the prior year.
  • Other financing activities was $1.2 million for Q4 2024 at Oramed Pharmaceuticals, up from $286000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $11.7 million in Q4 2022 and bottomed at -$1.8 million in Q2 2023.
  • Average Other financing activities over 3 years is $1.0 million, with a median of $106000.0 recorded in 2022.
  • The sharpest move saw Other financing activities plummeted 855.66% in 2023, then surged 1142.28% in 2024.
  • Year by year, Other financing activities stood at $11.7 million in 2022, then plummeted by 88.43% to $1.4 million in 2023, then fell by 10.13% to $1.2 million in 2024.
  • Business Quant data shows Other financing activities for ORMP at $1.2 million in Q4 2024, $286000.0 in Q3 2024, and -$1.2 million in Q2 2024.